Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

Literature DB >> 11514412

Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

Y Hijazi¹, M Bolon, R Boulieu.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2001 PMID： 11514412

Source DB: PubMed Journal: Clin Chem ISSN： 0009-9147 Impact factor: 8.327

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

Authors: Yibai Li; Kate A Jackson; Barry Slon; Janet R Hardy; Michael Franco; Leeroy William; Peter Poon; Janet K Coller; Mark R Hutchinson; David C Currow; Andrew A Somogyi
Journal: Br J Clin Pharmacol Date: 2015-06-01 Impact factor: 4.335

2. Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.

Authors: Sophie C Turfus; Mark C Parkin; David A Cowan; John M Halket; Norman W Smith; Robin A Braithwaite; Simon P Elliot; Glyn B Steventon; Andrew T Kicman
Journal: Drug Metab Dispos Date: 2009-05-15 Impact factor: 3.922

3. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Authors: Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould
Journal: J Pharmacol Exp Ther Date: 2016-07-28 Impact factor: 4.030

4. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study.

Authors: Chui Chong; Stephan A Schug; Madhu Page-Sharp; Barry Jenkins; Kenneth F Ilett
Journal: Clin Drug Investig Date: 2009 Impact factor: 2.859

Stability of ketamine and its metabolites norketamine and dehydronorketamine in human biological samples.

1. CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

2. Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.

3. Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

4. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study.

5. Ketamine and norketamine stability in whole blood at ambient and 4°C conditions.

Review 6. Ketamine-New Possibilities in the Treatment of Depression: A Narrative Review.

Review 7. Metabolism and metabolomics of ketamine: a toxicological approach.